Residential College | false |
Status | 已發表Published |
Bilirubin Nanomedicines for the Treatment of Reactive Oxygen Species (ROS)-Mediated Diseases | |
Chen,Zhejie1; Vong,Chi Teng1; Gao,Caifang1; Chen,Shiyun1; Wu,Xu2; Wang,Shengpeng1; Wang,Yitao1 | |
Source Publication | Molecular Pharmaceutics |
ISSN | 1543-8384 |
2020-05-20 | |
Abstract | Reactive oxygen species (ROS) are chemically reactive species that are produced in cellular aerobic metabolism. They mainly include superoxide anion, hydrogen peroxide, hydroxyl radicals, singlet oxygen, ozone, and nitric oxide and are implicated in many physiological and pathological processes. Bilirubin, a cardinal pigment in the bile, has been increasingly investigated to treat cancer, diabetes, ischemia-reperfusion injury, asthma, and inflammatory bowel diseases (IBD). Indeed, bilirubin has been shown to eliminate ROS production, so it is now considered as a promising therapeutic agent for ROS-mediated diseases and can be used for the development of antioxidative nanomedicines. This review summarizes the current knowledge of the physiological mechanisms of ROS production and its role in pathological changes and focuses on discussing the antioxidative effects of bilirubin and its application in the experimental studies of nanomedicines. Previous studies have shown that bilirubin was mainly used as a responsive molecule in the microenvironment of ROS overproduction in neoplastic tissues for the development of anticancer nanodrugs; however, it could also exert powerful ROS scavenging activity in chronic inflammation and ischemia-reperfusion injury. Therefore, bilirubin, as an inartificial ROS scavenger, is expected to be used for the development of nanomedicines against more diseases due to the universality of ROS involvement in human pathological conditions. |
Keyword | Bilirubin Cancer Inflammation Nanoparticle Ros |
Language | 英語English |
DOI | 10.1021/acs.molpharmaceut.0c00337 |
URL | View the original |
Volume | 17 |
Issue | 7 |
Pages | 2260-2274 |
WOS ID | WOS:000548455300004 |
WOS Subject | Medicine, Research & Experimental ; Pharmacology & Pharmacy |
WOS Research Area | Research & Experimental Medicine ; Pharmacology & Pharmacy |
Indexed By | SCIE |
Scopus ID | 2-s2.0-85087529063 |
Fulltext Access | |
Citation statistics | |
Document Type | Review article |
Collection | Institute of Chinese Medical Sciences THE STATE KEY LABORATORY OF QUALITY RESEARCH IN CHINESE MEDICINE (UNIVERSITY OF MACAU) |
Corresponding Author | Wang,Shengpeng; Wang,Yitao |
Affiliation | 1.State Key Laboratory of Quality Research in Chinese Medicine,Institute of Chinese Medical Sciences,University of Macau,999087,Macao 2.Laboratory of Molecular Pharmacology,Department of Pharmacology,Southwest Medical University,Luzhou,646000,China |
First Author Affilication | Institute of Chinese Medical Sciences |
Corresponding Author Affilication | Institute of Chinese Medical Sciences |
Recommended Citation GB/T 7714 | Chen,Zhejie,Vong,Chi Teng,Gao,Caifang,et al. Bilirubin Nanomedicines for the Treatment of Reactive Oxygen Species (ROS)-Mediated Diseases[J]. Molecular Pharmaceutics, 2020, 17(7), 2260-2274. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment